ERBB2 and gastric cancer: 89Zr-Trastuzumab PET/CT is an imaging test using radionuclide 89Zr-labeled trastuzumab as an imaging agent to determine HER2 expression heterogeneity in gastric cancers and the effect of HER2-targeted therapy.